Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification.

Humans Papillomavirus Infections / complications Retrospective Studies Neoplasm Recurrence, Local Oropharyngeal Neoplasms / therapy Squamous Cell Carcinoma of Head and Neck Prognosis Biomarkers Human Papillomavirus Viruses Head and Neck Neoplasms Papillomaviridae
Biomarkers Cancer immunology De-escalation HPV Head and neck squamous cell carcinoma Transcriptomics

Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 09 08 2022
revised: 02 11 2022
accepted: 04 11 2022
pubmed: 29 11 2022
medline: 21 12 2022
entrez: 28 11 2022
Statut: ppublish

Résumé

There is significant interest in treatment de-escalation for human papillomavirus-associated (HPV We created an immune score (UWO3) associated with survival outcomes in six independent cohorts comprising 906 patients, including blinded retrospective and prospective external validations. Two aggressive radiation de-escalation cohorts were used to assess the ability of UWO3 to identify patients who recur. Multivariate Cox models were used to assess the associations between the UWO3 immune class and outcomes. A three-gene immune score classified patients into three immune classes (immune rich, mixed, or immune desert) and was strongly associated with disease-free survival in six datasets, including large retrospective and prospective datasets. Pooled analysis demonstrated that the immune rich group had superior disease-free survival compared to the immune desert (HR = 9.0, 95% CI: 3.2-25.5, P = 3.6 × 10 With additional prospective validation, the UWO3 score could enable biomarker-driven clinical decision-making for patients with HPV CIHR, European Union, and the NIH.

Sections du résumé

BACKGROUND BACKGROUND
There is significant interest in treatment de-escalation for human papillomavirus-associated (HPV
METHODS METHODS
We created an immune score (UWO3) associated with survival outcomes in six independent cohorts comprising 906 patients, including blinded retrospective and prospective external validations. Two aggressive radiation de-escalation cohorts were used to assess the ability of UWO3 to identify patients who recur. Multivariate Cox models were used to assess the associations between the UWO3 immune class and outcomes.
FINDINGS RESULTS
A three-gene immune score classified patients into three immune classes (immune rich, mixed, or immune desert) and was strongly associated with disease-free survival in six datasets, including large retrospective and prospective datasets. Pooled analysis demonstrated that the immune rich group had superior disease-free survival compared to the immune desert (HR = 9.0, 95% CI: 3.2-25.5, P = 3.6 × 10
INTERPRETATION CONCLUSIONS
With additional prospective validation, the UWO3 score could enable biomarker-driven clinical decision-making for patients with HPV
FUNDING BACKGROUND
CIHR, European Union, and the NIH.

Identifiants

DOI: 10.1016/j.ebiom.2022.104373 PMID: 36442320 PMC: PMC9706534
pubmed: 36442320
pii: S2352-3964(22)00555-2
doi: 10.1016/j.ebiom.2022.104373
pmc: PMC9706534
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104373

Subventions

Organisme : NIDCR NIH HHS
ID : R01 DE026471
Pays : United States

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests PYFZ, JWB, PCB, JSM and ACN have a US patent pending for the UWO3 score. All other authors declare no conflict of interest.

Auteurs

Peter Y F Zeng (PYF)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.

Matthew J Cecchini (MJ)

Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.

John W Barrett (JW)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.

Matthew Shammas-Toma (M)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.

Loris De Cecco (L)

Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumouri, Milan, Italy.

Mara S Serafini (MS)

Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumouri, Milan, Italy.

Stefano Cavalieri (S)

Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumouri, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Lisa Licitra (L)

Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumouri, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Frank Hoebers (F)

Department of Radiation Oncology (MAASTRO), Research Institute GROW, Maastricht University, Maastricht, the Netherlands.

Ruud H Brakenhoff (RH)

Amsterdam UMC, Vrije Universiteit Amsterdam, Otolaryngology/Head and Neck Surgery, Cancer Center Amsterdam, the Netherlands.

C René Leemans (CR)

Amsterdam UMC, Vrije Universiteit Amsterdam, Otolaryngology/Head and Neck Surgery, Cancer Center Amsterdam, the Netherlands.

Kathrin Scheckenbach (K)

Department of Otolaryngology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Tito Poli (T)

Unit of Maxillofacial Surgery, Department of Medicine and Surgery, University of Parma-University Hospital of Parma, Parma, Italy.

Xiaowei Wang (X)

Department of Pharmacology and Regenerative Medicine, The University of Illinois at Chicago, Chicago, IL, USA.

Xinyi Liu (X)

Department of Pharmacology and Regenerative Medicine, The University of Illinois at Chicago, Chicago, IL, USA.

Francisco Laxague (F)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.

Eitan Prisman (E)

Division of Otolaryngology- Head and Neck Surgery, Department of Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada.

Catherine Poh (C)

Division of Otolaryngology- Head and Neck Surgery, Department of Surgery, Vancouver General Hospital, Vancouver, British Columbia, Canada; Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Pinaki Bose (P)

Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, University of Calgary, Calgary, Alberta, Canada.

Joseph C Dort (JC)

Division of Otolaryngology - Head and Neck Surgery, Department of Surgery, University of Calgary, Calgary, Alberta, Canada.

Mushfiq H Shaikh (MH)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.

Sarah E B Ryan (SEB)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.

Alice Dawson (A)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.

Mohammed I Khan (MI)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.

Christopher J Howlett (CJ)

Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.

William Stecho (W)

Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.

Paul Plantinga (P)

Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada.

Sabrina Daniela da Silva (S)

Department of Otolaryngology Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.

Michael Hier (M)

Department of Otolaryngology Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.

Halema Khan (H)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada.

Danielle MacNeil (D)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.

Adrian Mendez (A)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.

John Yoo (J)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.

Kevin Fung (K)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.

Pencilla Lang (P)

Department of Oncology, University of Western Ontario, London, Ontario, Canada.

Eric Winquist (E)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.

David A Palma (DA)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada.

Hedyeh Ziai (H)

Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.

Antonio L Amelio (AL)

Lineberger Comprehensive Cancer Center, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Cell Biology and Physiology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Shawn S-C Li (SS)

Department of Biochemistry, University of Western Ontario, London, Ontario, Canada.

Paul C Boutros (PC)

Department of Human Genetics, University of California, Los Angeles, CA, USA; Department of Urology, University of California, Los Angeles, CA, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA, USA; Institute for Precision Health, University of California, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, CA, USA.

Joe S Mymryk (JS)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada; Department of Microbiology & Immunology, University of Western Ontario, London, Ontario, Canada.

Anthony C Nichols (AC)

Department of Otolaryngology - Head and Neck Surgery, University of Western Ontario, London, Ontario, Canada; Department of Oncology, University of Western Ontario, London, Ontario, Canada. Electronic address: anthony.nichols@lhsc.on.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immune-based classification of HPV-associated...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies transmissibles › Maladies sexuellement transmissibles › Maladies sexuellement transmissibles virales › Infections à papillomavirus › Immune-based classification of HPV-associated...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Immune-based classification of HPV-associated...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Immune-based classification of HPV-associated...
questionsmedicales.fr › Maladies oto-rhino-laryngologiques › Maladies du pharynx › Tumeurs du pharynx › Tumeurs de l'oropharynx › Immune-based classification of HPV-associated...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Carcinome épidermoïde de la tête et du cou › Immune-based classification of HPV-associated...
questionsmedicales.fr › Diagnostic › Pronostic › Immune-based classification of HPV-associated...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Immune-based classification of HPV-associated...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Papillomaviridae › Virus des Papillomavirus humains › Immune-based classification of HPV-associated...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Immune-based classification of HPV-associated...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Papillomaviridae › Immune-based classification of HPV-associated...